Biofrontera AG (ETR:B8FK)

Market Cap	14.83M +3.8%
Revenue (ttm)	13.19M -27.4%
Net Income	-3.97M
EPS	-0.65
Shares Out	6.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	135
Average Volume	987
Open	2.500
Previous Close	2.410
Day's Range	2.370 - 2.500
52-Week Range	2.160 - 2.960
Beta	-0.17
RSI	45.44
Earnings Date	Apr 17, 2026

About Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 74
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: B8FK

Financial Performance

In 2025, Biofrontera AG's revenue was 13.19 million, an increase of 8.26% compared to the previous year's 12.18 million. Losses were -3.97 million, -8.85% less than in 2024.